LAG3 and myocarditis: Similarly, recent trials involving combined nivolumab (anti-PD-1 mAb) and relatlimab (anti-LAG-3 mAb) therapy revealed slightly elevated instances of myocarditis in comparison to the usage of single nivolumab (anti-PD-1 mAb) therapy (1.7% versus 0.6%, respectively) (117).